Recent Analysts’ Ratings Changes for Nurix Therapeutics (NRIX)

Nurix Therapeutics (NASDAQ: NRIX) has recently received a number of price target changes and ratings updates:

• 10/17/2026 – Nurix Therapeutics was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/16/2026 – Nurix Therapeutics had its price target raised by HC Wainwright from $34.00 to $36.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/13/2026 – Nurix Therapeutics had its price target lowered by Royal Bank Of Canada from $36.00 to $35.00. They now have an “outperform” rating on the stock.
• 10/13/2026 – Nurix Therapeutics had its price target raised by Oppenheimer from $28.00 to $32.00. They now have an “outperform” rating on the stock.
• 10/13/2026 – Nurix Therapeutics was given a new $41.00 price target by Stifel Nicolaus.
• 10/13/2026 – Nurix Therapeutics had its price target lowered by Truist Financial from $34.00 to $33.00. They now have a “buy” rating on the stock.
• 10/13/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
• 10/13/2026 – Nurix Therapeutics had its price target raised by Robert W. Baird from $33.00 to $36.00. They now have an “outperform” rating on the stock.
• 9/26/2026 – Nurix Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/5/2026 – Nurix Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock traded up $0.68 on Tuesday, reaching $26.38. The stock had a trading volume of 232,510 shares, compared to its average volume of 1,574,049. The business’s 50-day moving average price is $24.96 and its two-hundred day moving average price is $20.23. Nurix Therapeutics, Inc. has a fifty-two week low of $11.67 and a fifty-two week high of $28.23. The stock has a market cap of $2.88 billion, a P/E ratio of 11.42 and a beta of 1.82.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. The business had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. As a group, equities analysts forecast that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Hans van Houte sold 2,834 shares of the firm’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $26.28, for a total value of $74,477.52. Following the sale, the chief financial officer directly owned 47,514 shares of the company’s stock, valued at approximately $1,248,667.92. This trade represents a 5.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $26.80, for a total value of $38,913.60. Following the completion of the transaction, the insider owned 123,452 shares in the company, valued at $3,308,513.60. The trade was a 1.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,086 shares of company stock worth $928,006 over the last ninety days. Company insiders own 6.70% of the company’s stock.

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.